Datopotamab deruxtecan

德达博妥单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameDatopotamab deruxtecan
Drug Alias NameDatopotamab deruxtecan-dlnkDato-DXdTROP2-directed ADCDatrowayDATROWAY +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload > MAAA-1181a payload
Mechanisms of ActionTumor-associated calcium signal transducer 2 inhibitorsDNA topoisomerase I inhibitors
TargetsTumor-associated calcium signal transducer 2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm, Residual +[17] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryJapan
Original Approved Date2024/12/27
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdDaiichi Sankyo Europe GmbhDaiichi Sankyo Inc +[10] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm, Residual +[17] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG